Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-10-30 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2023-10-30 English
Appendix 4G and Corporate Governance Statement 22 pages 589.8KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a governance-related filing that provides a key to where corporate governance disclosures can be found, confirms compliance with ASX Corporate Governance Council recommendations, and includes URLs and references to the corporate governance statement and annual report. The document explicitly states it is not a substitute for the corporate governance statement but serves as a verification tool for disclosure requirements. It is a regulatory filing related to governance disclosures but does not contain the full governance report itself. The document is about corporate governance disclosures and compliance, fitting the category of Governance Information (CGR). It is not an annual report, audit report, or other financial report, nor is it an announcement or proxy material. Therefore, the best classification is Governance Information (CGR).
2023-10-29 English
Notice of Annual General Meeting and Proxy Form 30 pages 650.7KB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting and Explanatory Memorandum' for Mesoblast Limited's AGM scheduled for 28 November 2023. It includes details about the meeting time, venue, voting procedures, items of business such as receipt and consideration of financial statements and reports, adoption of the remuneration report, amendments to the constitution, re-election of directors, and approval of proposed issue of options to executives and directors. The document is clearly a notice and explanatory memorandum for the AGM, which is a presentation and materials shared during the Annual General Meeting. It is not the annual report itself, nor a voting results announcement, nor a management or earnings report. The length (15,000 characters) and content confirm it is a detailed AGM notice and explanatory memorandum, fitting the AGM Information category.
2023-10-29 English
Annual Report to Shareholders 256 pages 4.7MB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2023' and contains extensive content typical of an annual report, including a message from the chairman, CEO report, corporate governance statement, detailed discussion of company strategy, product development, FDA interactions, and financial prudence. It references the fiscal year ending 30 June 2023 and includes a Form 20-F, which is a type of annual report filed by foreign private issuers with the SEC. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K equivalent for foreign companies).
2023-10-29 English
6-K
Regulatory Filings
2023-10-18 English
Notification regarding unquoted securities - MSB 6 pages 28.5KB
Share Issue/Capital Change Classification · 95% confidence The document is a notification regarding the issue, conversion, or payment up of unquoted equity securities by Mesoblast Limited. It details the number and types of securities issued, dates, and compliance with ASX listing rules. The content focuses on capital changes related to employee incentive schemes and unquoted securities, without financial statements or management discussion. This fits the category of announcements about share issues or capital changes rather than a full financial report or other regulatory filings. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and detail support this classification with high confidence.
2023-10-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.